The Psychedelic Renaissance Begins (Again)

Not long ago, the idea of magic mushrooms as medicine seemed laughable.
Today, psychedelics are riding a cultural and scientific wave, much like
cannabis did years before. Research at top universities, growing clinical
trials and personal stories of healing have fueled what many now call a
“psychedelic renaissance.”

Public perception has shifted at lightning speed. Stigma gave way to
curiosity, taboo to tool, fear to fascination. A decade ago, cannabis had
its own version of this moment. Once demonized, it’s now a normalized part
of wellness culture. Psychedelics are following a similar trajectory,
gaining legitimacy through science, changing laws and cultural momentum.

In Oregon, the first licensed service centers opened in 2023 where adults
can legally access guided psilocybin sessions. Colorado followed,
decriminalizing personal use and creating a regulated model for “natural
medicine.” More states are lining up, and cities such as Oakland and Denver
continue to drive decriminalization. Globally, Canada, the Netherlands,
Spain and Jamaica are shaping markets through research, retreats and
religious or therapeutic exemptions.

The lesson is clear: As cannabis proved, laws can shift when culture leads.
Now psychedelics are positioned not as competitors to cannabis but rather
complementary forces within a growing global wellness economy.

Cannabis created the blueprint. Grassroots advocacy, patient-driven medical
research, innovative retail models and cultural normalization all paved the
way for a once-taboo plant to go mainstream. Some of the pioneers who
helped cannabis take root now channel that hard-won knowledge into
psychedelics.

Field Trip Health, for example, operates ketamine-assisted therapy clinics
across North America, and is preparing for psilocybin once legal. Their
model borrows directly from dispensaries (safe, welcoming spaces where
people can access medicine under professional guidance).

Big-name cannabis veterans including Bruce Linton, former CEO of Canopy
Growth, invests in psychedelic firms—he serves as chairman of the advisory
board for Netherlands-based Red Light Holland and sat on the board of New
York-based MindMed until 2021. For executives who have already scaled
cannabis companies, psychedelics represent the next frontier, with cannabis
as proof of concept.

This cross-pollination accelerates growth. Cannabis brands bring regulatory
know-how, cultivation expertise and consumer trust. Psychedelic startups,
in turn, expand the palette of plant-based healing and connect with new
audiences. It’s not competition—it’s cross-training.

What makes this renaissance so exciting is that psychedelic brands are
building with cannabis lessons in mind—prioritizing authenticity, community
and consumer education. From grassroots innovators to clinical labs, these
companies echo cannabis’s core ethos of authenticity, safety and
accessibility.

Take Lady Hyphae, a Denver-based grow-kit company founded by Danielle
Adams, who cut her teeth in cannabis cultivation before turning to
mushrooms. “Cannabis taught us that people want access, not gatekeeping,”
Adams says. “Workshops and kits aren’t just about mushrooms; they’re about
empowerment, community and reclaiming healing on our own terms.” Her
woman-forward branding and emphasis on education mirror the early days of
legacy cannabis collectives, where growers passed down knowledge long
before dispensaries existed.

Thinking Caps, a California-based wellness brand blending functional and
entheogenic mushrooms (using the whole fruiting body) into bright,
fruit-flavored gummies designed for focus, creativity, and cognitive
clarity. Founder Lauren Stanko says their products are single sourced for
purity and consistency, echoing the evolution of cannabis edibles from
their start as underground brownies to their current explosion into the
high-end gourmet and luxury wellness worlds. “These aren’t just feel-good
party favors; they’re powerful daily allies,” Stanko says. “We offer
something familiar and functional that fits naturally into people’s
wellness routines, no matter who they are.”

Consumers asking for products that bridge the familiar territory of
cannabis with the lesser-known world of psychedelics are gravitating toward
brands with fun and colorful, yet sleek and sophisticated design aesthetics
that are carried out with intention. This opportunity for brand
storytelling around myco-wellness is helping mushrooms integrate into
mainstream self-care at a rapid pace in a market seeking transparency,
ethics and *style*.

Highlighting the diversity of this ecosystem is Culture Shrooms, a
California dispensary-style café with mushroom-infused cold brew and teas
with cannabis lounge vibes.

Substrate manufacturers such as PooGod and Twisted Tree Nursery are
redefining soil science for fungi, like hydro stores did for weed. Twisted
Tree Nursery’s “DinoSoil” (a mix of tortoise, camel, alpaca and donkey
manure) is used to bump fungal yields in the same way other cultivators
play with different inputs and mediums.

International players like Valenveras in Spain, together with Magic Myco
and Full Canopy Genetics, are pioneering potency testing, applying the
cannabis lab-testing playbook of pesticides, solvents and safety standards
to psychedelics. On the clinical side, Compass Pathways is in late-stage
trials to potentially deliver the first FDA-approved psilocybin therapy.

For everyday users, this convergence means more choice and flexibility.
Cannabis is often used as daily medicine for easing stress, anxiety,
sleeplessness and pain— without substantially disrupting one’s routines.
Psychedelics, on the other hand, are more occasional, yet still profoundly
transformative with a single session reportedly being enough to rewire
users’ relationship with trauma, depression or spiritual growth.

Complementary when used together, cannabis may integrate insights from a
psilocybin journey, grounding the user during aftercare and even easing
physical discomforts like nausea. Psychedelics, in turn, can deepen the
emotional or spiritual healing cannabis consumers may seek.

Each path is ultimately about empowerment, not dependency.

The product overlaps are comforting, with psychedelics being more
approachable for those already comfortable with natural remedies such as
microdosing, which resembles low-dose THC or CBD supplements. Infused
drinks, gummies and capsules are akin to common cannabis edibles, some even
sold in alcohol chains. Even the two industries’ marketing lexicons overlap
(“plant medicine,” “wellness journeys,” “mindful healing,”
“set-and-setting”). Together, they’re creating a wellness ethos centered on
safety and transparency.

The cultural throughline exists beyond products, in the normalization of
conversations about mental health and holistic healing, paving the way for
more open discussions on psychedelics. Just as the cannabis industry
invested in consumer education, psychedelic advocates are pushing hard to
emphasize intentional, guided use over recreational misuse to prevent a
public relations nightmare and quell public safety concerns.

The future of wellness is holistic, integrative and rooted in nature.
Cannabis broke down the door so psychedelics can walk through it.

Canna-consumers can expect more crossover products, shared retail models
and collaborative education. A psychedelics line may diversify portfolios
of cannabis companies, extend distribution channels and stay competitive in
a fast-shifting marketplace. For society, the message is clear: Nature’s
medicines, plant or fungus, are powerful allies when used responsibly.

It’s not cannabis versus mushrooms. It’s cannabis *and* mushrooms, forming
a unified frontier of wellness, changing how we heal, connect and how we
imagine the future of health.

The post The Psychedelic Renaissance Begins (Again) appeared first on Cannabis
Now.